GI & Endoscopy

Becker's ASC Review profiled nine gastroenterologists in November:

Here is how five major, publicly traded gastroenterology companies fared in the stock market for the week of Nov. 20 to Nov. 24, 2017.

GlobalData analysts expect there will be 1.96 million Crohn's disease patients globally by 2026, according to a market analysis.

A study, published in Diseases of The Colon and Rectum, examined how waiting for surgery impacted survival rate in stage I to stage III colon cancer patients.

Here are six updates on GI companies from the past week:

IQuity is releasing IsolateIBS-IBD, a RNA-based blood test that can help physicians identify irritable bowel syndrome or inflammatory bowel disease.

A study, published in CA: A Cancer Journal for Clinicians, estimated the proportion and number of invasive cancer cases and deaths that were attributable to major, potentially changeable factors.

Donald Gerhardt, MD, is a gastroenterologist at Gastrointestinal Associates in Columbia, Mo.

Here is how five major, publicly traded gastroenterology companies fared in the stock market for the week of Nov. 13 to Nov. 17.

After discontinuing a drug therapy program that "did not live up to its promise," Outpost Medicine shifted its focus towards OP-687, an oral therapy for overactive bladder and irritable bowel syndrome, IBJ reports.